ArticleJournal of biological engineering2026
Chitin nanowhiskers/octacalcium phosphate synergistically reinforced chitosan hydrogel for enhanced bone regeneration.
Article in Journal of biological engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The repair of jawbone defects faces critical challenges, such as the mechanical-bioactivity imbalance and limited bioactivity of traditional scaffold materials. This study proposes a “mechanical reinforcement–bio-mineralization” synergistic strategy to construct a chitin nanowhiskers (CHWs)/octacalcium phosphate (OCP) co-modified chitosan (CS) composite hydrogel (CS/CHWs-OCP) and systematically investigates its bone regeneration efficacy. Results demonstrate the successful fabrication of CS/CHWs-OCP hydrogels with gradient OCP loading (3%–12% wt). The hydrogels exhibit three-dimensional interconnected porous structures, favorable swelling properties, and effective protein loading/sustained-release capabilities. In vitro experiments reveal that CS/CHWs-OCPs significantly promote osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs) and angiogenic differentiation of EA.hy926 cells, with the 12 wt% OCP group showing the highest alkaline phosphatase (ALP) activity. Micro-CT 3D reconstruction and histological analysis demonstrate that the 12 wt% OCP group exhibits optimal calvarial defect repair capacity, with its new bone volume fraction (BV/TV: 57.2 ± 10.2%) at 8 weeks being significantly superior to both the blank control and OCP-free hydrogel groups. In conclusion, the developed CS/CHWs-OCP hydrogel provides an effective solution for bone defect regeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.